For the chart of the week we wanted to explore the market for multi-analyte panels. We found that single biomarker tests still vastly outnumber panels. Stay tuned for more trending information in the coming weeks. My hypothesis: Panels, even outside of NGS, are being introduced to the market faster than single biomarker tests.
Share this Image On Your Site
For a refresher on Amplion and BiomarkerBase: